ACIU:NSD-AC Immune SA (USD)

COMMON STOCK | Other | NSD

Last Closing Price

USD 6.35

Change

-0.29 (-4.37)%

Market Cap

USD 0.34B

Volume

0.18M

Average Target Price

USD 11.00 (+73.23%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company's lead product candidate is crenezumab, a humanized, monoclonal, and conformation-specific anti-Abeta antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as is in Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; RG6100, an anti-Tau antibody candidate, which is in Phase II clinical study for AD patients; and Tau-PET imaging tracer that has completed Phase I clinical study. In addition, the company is researching and developing Tau Morphomer aggregation inhibitor small molecules for AD. Further, it has discovery and pre-clinical stage molecules targeting neurodegenerative diseases, as well as diagnostics targeting Tau, alpha-synuclein, and TDP-43 aggregates. The company has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; Essex Bio-Technology Limited; and WuXi Biologics. It also has a research collaboration with University of Pennsylvania to focus on pathogenic protein TDP-43 in neurodegenerative diseases. AC Immune SA was founded in 2003 and is headquartered in Lausanne, Switzerland.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-03-27 )

Largest Industry Peers for Other

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
LGCY Legacy Reserves Inc

N/A

USD61,525,874.67B 1.10 N/A
FTD FTD Companies, Inc

N/A

USD28,725,913.80B N/A N/A
KEYW The KeyW Holding Corporation

N/A

USD24,651,104.38B 166.80 N/A
SNHY Helios Technologies, Inc

N/A

USD17,848,852.22B 1,000,000.00 N/A
QTNA Quantenna Communications, Inc

N/A

USD8,997,243.52B 1,000,000.00 N/A
INSY INSYS Therapeutics, Inc

N/A

USD4,995,459.82B 115.90 N/A
CHKE Apex Global Brands Inc

N/A

USD384,202.91B 17.30 N/A
AMCN AirNet Technology Inc

N/A

USD308,457.30B 1.00 N/A
PDVW pdvWireless, Inc

N/A

USD95,944.74B N/A N/A
AIPT Predictive Oncology Inc

N/A

USD38,513.36B N/A N/A

ETFs Containing ACIU

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Other)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -25.47% 51% F 54% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -25.47% 50% F 54% F
Trailing 12 Months  
Capital Gain 29.33% 87% B+ 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 29.33% 87% B+ 91% A-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -10.18% 34% F 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.18% 33% F 16% F
Risk Return Profile  
Volatility (Standard Deviation) 31.92% 83% B 55% F
Risk Adjusted Return -31.89% 28% F 14% F
Market Capitalization 0.34B 61% D- 59% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Other)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 18.30 53% F 44% F
Price/Book Ratio 1.57 52% F 46% F
Price / Cash Flow Ratio -7.47 77% C+ 84% B
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity 20.73% 91% A- 89% B+
Return on Invested Capital -17.37% 37% F 28% F
Return on Assets 11.66% 97% A+ 96% A
Debt to Equity Ratio 0.10% 85% B 89% B+
Technical Ratios  
Short Ratio 2.16 61% D- 60% D-
Short Percent 1.09% 76% C 73% C
Beta 0.73 57% F 65% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector